Pre-made Zenocutuzumab benchmark antibody ( Bispecific mAb, anti-ERBB3/Erbb-3;ERBB2/HER2 therapeutic antibody, Anti-FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-645
Pre-Made Zenocutuzumab biosimilar, Bispecific mAb, Anti-ERBB3/Erbb-3;ERBB2/HER2 Antibody: Anti-FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-645-1mg | 1mg | Inquiry | ||
GMP-Bios-ab-645-10mg | 10mg | Inquiry | ||
GMP-Bios-ab-645-100mg | 100mg | Inquiry | ||
GMP-Bios-ab-645-xmg | >100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Zenocutuzumab biosimilar, Bispecific mAb, Anti-ERBB3/Erbb-3;ERBB2/HER2 Antibody: Anti-FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody |
INN Name | Zenocutuzumab |
Target | Erbb-3;HER2 |
Format | Bispecific mAb |
Derivation | Bispecific antibody |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa;Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Active |
100% SI Structure | 5o4o:BA/5o7p:BA;5o4g:BA |
99% SI Structure | None;None |
95-98% SI Structure | None;None |
Year Proposed | 2017 |
Year Recommended | 2018 |
Companies | Merus |
Conditions Approved | na |
Conditions Active | Breast cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer |
Conditions Discontinued | Endometrial cancer;Ovarian cancer |
Development Tech | GlymaxX Technology |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<